SEC Form 4 · accession 0001214659-18-001007
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Christensen
Officer — SVP, Chief Scientific Officer
Period of report
Feb 6, 2018
Accepted (ET)
Feb 8, 2018 · 6:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 6, 2018 | M | 8,000 | $17.41 | A | 10,877 | D | |
| Common Stock | Feb 6, 2018 | M | 7,500 | $24.99 | A | 18,377 | D | |
| Common Stock | Feb 6, 2018 | M | 7,500 | $21.51 | A | 25,877 | D | |
| Common Stock | Feb 6, 2018 | S | 23,000 | $30.00 | D | 2,877 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $17.41 | Feb 6, 2018 | M | 8,000 | D | — | May 20, 2024 | Common Stock | 8,000 | 25,936 | D |
| Employee Stock Option (Right to Buy)F2 | $24.99 | Feb 6, 2018 | M | 7,500 | D | — | Jan 21, 2026 | Common Stock | 7,500 | 52,500 | D |
| Employee Stock Option (Right to Buy)F2 | $21.51 | Feb 6, 2018 | M | 7,500 | D | — | Feb 3, 2025 | Common Stock | 7,500 | 22,500 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2017.
- F21/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.